Vir Biotechnology Inc VIR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if VIR is a good fit for your portfolio.
News
-
Vir Biotechnology Announces Nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of Directors
-
Vir Biotechnology to Provide Business Update and Report First Quarter 2024 Financial Results on May 2, 2024
-
Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule
-
Vir Biotechnology to Participate in Upcoming Investor Healthcare Conferences
-
Vir Biotechnology, GSK Terminate Collaboration on Flu
-
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
-
Vir Biotechnology Announces Dr. Phil Pang Will Step Down as Chief Medical Officer
-
Vir Biotechnology to Provide Business Update and Report Fourth Quarter 2023 Financial Results on February 22, 2024
Trading Information
- Previous Close Price
- $8.25
- Day Range
- $7.94–8.31
- 52-Week Range
- $7.72–27.48
- Bid/Ask
- $7.14 / $9.67
- Market Cap
- $1.07 Bil
- Volume/Avg
- 1.1 Mil / 1.0 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 28.39
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 587
- Website
- https://www.vir.bio
Comparables
Valuation
|
Metric
|
VIR
|
ALVR
|
NWBO
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 0.71 | 0.58 | — |
Price/Sales | 28.39 | — | 292.87 |
Price/Cash Flow | — | — | — |
Price/Earnings
VIR
ALVR
NWBO
Financial Strength
|
Metric
|
VIR
|
ALVR
|
NWBO
|
|---|---|---|---|
Quick Ratio | 8.68 | 6.49 | 0.05 |
Current Ratio | 9.05 | 6.61 | 0.09 |
Interest Coverage | — | — | −10.94 |
Quick Ratio
VIR
ALVR
NWBO
Profitability
|
Metric
|
VIR
|
ALVR
|
NWBO
|
|---|---|---|---|
Return on Assets (Normalized) | −20.03% | −52.75% | −179.00% |
Return on Equity (Normalized) | −25.63% | −66.34% | — |
Return on Invested Capital (Normalized) | −28.31% | −59.54% | — |
Return on Assets
VIR
ALVR
NWBO
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Sgplyljty | Bcn | $550.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Fdxlwhy | Qlmzbp | $101.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Cjvxlyzn | Tfwpgj | $98.1 Bil | |
MRNA
| Moderna Inc | Zgtywst | Bgnh | $39.1 Bil | |
ARGX
| argenx SE ADR | Hbvqnjrj | Ywrrf | $21.7 Bil | |
BNTX
| BioNTech SE ADR | Hftpsxmqq | Fmvgp | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Kwdwzwvlz | Yqsbnl | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Vxzcqzdr | Fzxqvr | $17.1 Bil | |
RPRX
| Royalty Pharma PLC Class A | Yhfrbbzf | Dgvgs | $12.5 Bil | |
INCY
| Incyte Corp | Wgqlzlb | Ythwfj | $11.9 Bil |